Impact of New Antihypertensives on Healthcare Utilization by Hypertensive Patients
|
|
- Leonard Preston
- 5 years ago
- Views:
Transcription
1 At a Glance Pharmacoeconomics Practical Implications p 139 Author Information p 144 Full text and PDF Impact of New Antihypertensives on Healthcare Utilization by Hypertensive Patients Arijit Ganguli, PhD, MBA; and Song Hee Hong, PhD The rising cost of healthcare has always been a prime concern for policymakers, healthcare economists, healthcare payers, and society at large. It has been suggested that a significant reason for this escalating cost is use of the newer and more costly medications that are introduced in the market each year. Advocates who support acceptance and use of newer drugs argue that newer medications have better clinical outcomes, tend to reduce the overall healthcare cost, and contribute to increased quality of life and longevity. 1 The objective of this study was to verify the hypothesis that adoption of newer medications is associated with decreased healthcare cost and utilization of healthcare services among patients with hypertension. Our intention was to understand the relationship between new drug adoption and healthcare utilization from the patient s perspective. BACKGROUND Prescription drug expenditures accounted for 13% of total US healthcare expenditures in This cost soared from $50 billion spent in 1990 to $219 billion in Despite strong evidence from the famous Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial supporting the superiority of thiazide-type diuretics over other groups of antihypertensive medications, both in terms of clinical outcomes and treatment costs, use of newer medications has increased more than use of diuretics. 3-5 Joint National Committee guidelines recommend diuretics as the first choice in hypertensive patients with no comorbidities. 6 However, differences still exist between these guidelines and the initial drug of choice in clinical practice. 7 It is estimated that nearly $60 billion is spent on managing hypertension and its complications annually in the United States, yet only 34% of the patients treated with antihypertensive medications reach desired blood pressure goals. 6,8 Recent studies have stated that much of this increase in cost is attributable to the introduction of new and generally more costly brand name drugs that replace older, less expensive medications. 9 It is crucial to understand this current healthcare spending, as current ABSTRACT Objective: To investigate the hypothesis that adoption of newer antihypertensive medications is associated with decreased healthcare utilization in patients with hypertension. Study Design: Retrospective follow-up study. Methods: Hypertensive patients were identified during the first round of the 1999 Medical Expenditure Panel Survey database and followed until the end of the year. Antihypertensive drugs approved by the US Food and Drug Administration (FDA) in were defined as new antihypertensive drugs. New drug adopters were those hypertensive patients who were prescribed at least 1 new antihypertensive medication. Total healthcare expenditures, nondrug healthcare expenditures, and emergency department (ED) visits were the variables signifying healthcare utilization. Results: The FDA approved 14 new antihypertensive drugs in 1996, 1997, and Of the 1149 patients who met inclusion criteria, 63 (5.48%) were new drug adopters. The total healthcare and nondrug healthcare expenditures of the new drug adopters were found to be 1.63 (P =.019) and 1.78 (P =.013) times higher, respectively, than they were for patients who were not new drug adopters. The difference in ED visits between the 2 groups was not significant (P =.089). Conclusion: Adoption of new antihypertensive drugs led to higher healthcare costs with no significant difference in ED visits compared with old antihypertensive drugs. This result signifies the need to do a pharmacoeconomic evaluation of each new drug before acceptance by formulary strategists, physicians, and pharmacy managers. (Am J Pharm Benefits. 2009;1(3): ) Author affiliations and disclosures provided at the end of the text. 138 The American Journal of Pharmacy Benefits Fall
2 drug expenditures have been identified as strong predictors of future nondrug expenditures. 10 Policymakers, both private and public, have devised numerous ways to reject the replacement of older, less expensive drugs with newer costly drugs in the absence of proven improvement in outcomes. 2 The question every healthcare provider should address before prescribing a new and expensive treatment is whether the drug is worth the cost. Lichtenberg found that use of newer drugs reduced nondrug costs 3.9 to 7.2 times as much as it increased drug expenditures. 9 This study compared the drug age with healthcare expenditures. The drug age was defined as the number of years prior to 1996 that the active ingredient was first approved by the US Food and Drug Administration (FDA). Lichtenberg used the number of prescriptions as the unit of observation and found that, on average, replacing a 15-year-old drug with a 5.5-year-old drug would save $72 in nondrug healthcare spending and cost $18 more in drug spending, resulting in a drug offset effect of $54. In another study, Lichtenberg used the medical condition instead of prescriptions as the unit of observation and estimated a larger drug offset of $ One of the major limitations of this study was that it did not take into consideration the severity of illness of the patient. Zhang and Soumerai used a generalized linear model with a log link function and gamma distribution with the Medical Expenditure Panel Survey (MEPS) data and estimated $23 as the cost of new drugs after adjusting for illness severity, compared with $18 in the Lichtenberg study. 2 In a study of the new cardiovascular drugs, Miller et al controlled for the number or mix of drugs and found the relationship between the new drug spending and drug age to be statistically insignificant. 10 So these studies highlighted the fact that, on an aggregate level, the new drugs seemed to be worth the cost, although that may not be the case in specific disease states. The objective of this study was to analyze the impact of prescribing a new antihypertensive drug on total healthcare expenditures, nondrug healthcare expenditures, and emergency department (ED) visits in US patients with hypertension. We examined whether adopting a new antihypertensive drug was associated with changes in (1) total healthcare expenditures, (2) nondrug healthcare expenditures, and (3) total number of ED visits. This study included certain new drugs approved by the FDA after 1996 that were not considered in previous studies. METHODS We performed a retrospective follow-up study using the 1999 MEPS database. Patients were defined as Practical Implications Although previous studies have shown that new drugs decrease overall healthcare costs, this retrospective follow-up study of hypertensive patients came to the opposite conclusion. n Adopting new antihypertensive drugs increased total as well as nondrug costs in a real-world setting. n Pharmacoeconomic evaluation of new antihypertensive drugs should be done before they are accepted by formulary decision makers, payers, physicians, and pharmacy managers. hypertensive when they had a diagnosis of hypertension (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes ). Hypertensive patients during the first round of the year (round 3 of 1998 and round 1 of 1999) who had been prescribed at least 1 antihypertensive drug during that period (first round) were included in the study (see Figure). Analytic Overview Antihypertensive drugs approved by the FDA during 1996, 1997, and 1998 were defined as new antihypertensive drugs in this study. New drug adopters were those hypertensive patients who had been prescribed at least 1 of the identified new antihypertensive medications during the first round in Non new drug adopters were defined as those hypertensive patients in round 1 of 1999 who had not been prescribed any of the new antihypertensive drugs. Both populations were followed until the end of the year. The healthcare expenditure data at the end of the year were compared between the 2 groups. The number of unique medications for all conditions was used as a surrogate marker for the patient s comorbidity index. Prescriptions with similar active ingredient(s), irrespective of dosage form and strength, were considered unique medications. Total healthcare expenditure, as defined in MEPS, was the sum of direct payments for care provided during the year, including out-of-pocket payments and payments by private insurance, Medicaid, Medicare, and other sources. Payments for nonprescription drugs and alternative care services were not included in the MEPS total expenditures. Indirect payments not related to specific medical events, such as Medicaid Disproportionate Share and Medicare Direct Medical Education subsidies, also were not included. 12 Nondrug costs were determined by subtracting prescription drug costs from total healthcare costs. The VOL. 1, NO. 3 The American Journal of Pharmacy Benefits 139
3 n Ganguli Hong Figure. Diagrammatic Representation of the Study Rounds in the Medical Expenditure Panel Survey 1998 and 1999 Database January January December January Round 1 Round 2 Round 3 Round 1 Study period Round 4 Round 2 number of ED visits was taken as one of the outcome measures. All the results were adjusted for sex, age, race, ethnicity, severity of disease, income level, and type of insurance. The type of insurance was categorized as private, public, or uninsured. According to the Center for Drug Evaluation and Research data briefing, the FDA approved 102, 101, and 65 standard new drug applications (NDAs) in the years 1996, 1997, and 1998, respectively; of these standard NDAs, 35, 30, and 14 approvals were for standard new molecular entities for the years 1996, 1997, and 1998, respectively. 13 In the years 1996, 1997, and 1998, the FDA approved 3, 7, and 4 NDAs, respectively, for treatment of hypertension. 14 New drugs for this study included all new molecular entities, new molecules in previously existing drug classes, new product extensions (eg, extended/sustained-release dosage forms), and new combination drugs with an existing patent. Generic drugs and drugs with expired patents were not classified as new drugs. Hypertensive patients taking any 1 of these 14 new drugs were identified as new drug adopters. Of these 14 drugs, 7 were new molecules from previously existing drug classes, 3 were new product extensions, and 4 were new drug combinations. Round 5 Round 3 Table 1. Number of Observations in Each Step During Identification of Study Population in the MEPS 1999 Database Identification Step Unweighted Observations, n Total core survey (HC) file 24,618 Hypertensive patients 2721 Round Hypertensive with 1 antihypertensive medication 1149 New drug adopters 63 Non new drug adopters 1071 HC indicates Household Component of the MEPS; MEPS, Medical Expenditure Panel Survey. Data Analysis New drug adopters and non new drug adopters were compared for differences in demographic characteristics, income level, and type of insurance with the χ 2 test. A multiple regression analysis using a generalized linear model with a log link function and gamma distribution was used to analyze the association between new drug adopters and healthcare expenditures, adjusting for age, sex, race, ethnicity, income, severity of disease, and insurance type. Interpretation was done by taking the natural exponential [exp(β 1 )] of the regression coefficient for the expenditure variables. The association between new drug adoption and ED visits was analyzed using the ordinary least squares regression method. The variables that were compared and reported were total healthcare cost, nondrug cost, and total number of ED visits. All analysis was performed without any reference to the sample weights. The study sample was treated as simple random rather than stratified random. The level of statistical significance was P.05, and all statistical computations were done with SAS 9.1 software (SAS Institute Inc, Cary, NC). RESULTS Of 24,618 unweighted observations, 2721 (11.05%) represented patients who had been diagnosed with hypertension (ICD-9-CM codes ) in the 1999 MEPS database. A total of 1306 (47.99%) patients had been diagnosed as hypertensive in the first round of the 1999 MEPS survey; 1149 (87.97%) had been prescribed at least 1 antihypertensive medication and formed the final population for this study. Sixty-three patients (5.48%) were prescribed new antihypertensive drugs and hence grouped as new drug adopters (Table 1). No significant differences were observed between new drug users and non new drug users in terms of age, race, ethnicity, income, and insurance status, although new drug users were significantly more likely to be female (Table 2). The majority of new drug users and non new drug users (60.32% and 64.27%, respectively) were 140 The American Journal of Pharmacy Benefits Fall
4 Impact of New Antihypertensives younger than age 45 years. More than a third in both groups had an annual income below $20,000. About 79% of the new drug adopters were insured versus 88% of the non new drug users. Among insured patients, 80.0% of new drug adopters and 80.33% of non new drug adopters had private insurance. Both groups were dominated by Caucasians, mostly white non-hispanics; 77.78% and 78.55% of the new drug adopters and non new drug adopters, respectively, were whites. The results of the regression analysis showed that the total healthcare expenditure and the nondrug expenditure were significantly associated with adoption of new antihypertensive drugs (Table 3). Upon converting these values into their natural exponential form, the total healthcare expenditures and the nondrug healthcare expenditures of new drug adopters were found to be 1.63 (P =.019) and 1.79 (P =.013) times higher, respectively, than the corresponding expenditures of the non new drug adopters (Table 4). Though the new drug adopters had more ED visits than non new drug adopters, this difference was insignificant (P =.089). Age and income were significantly associated with total and nondrug expenditures. Hypertensive patients older than age 64 years had a 2-fold increase (P.001) in the total healthcare expenditure and about a 1.7-fold (P.001) increase in the nondrug expenditure compared with patients age 44 years or younger. Hypertensive patients age 45 to 64 years had total and nondrug healthcare expenditures 1.6 times (P.001) and 1.39 times (P =.011), respectively, greater than those of patients age 44 years or younger. The total and nondrug expenses of patients with annual incomes between $50,000 and $100,000 were 41% (P =.002) and 42% (P =.004) lower than those of patients with an annual income lower than $20,000. Those with annual incomes higher than $100,000 spent almost 52% (P =.017) and 60% (P =.007) less in terms of the total and nondrug expenses, respectively, than patients with an annual income lower than $20,000. African American patients had lower total and nondrug healthcare expenses than the Caucasians (0.16 times lower [P =.01] and 0.18 times lower [P =.027], respectively). Sex and ethnicity had no significant association with total and nondrug healthcare expenditures. Table 2. Characteristics of New Drug Adopters and Non New Drug Adopters New Drug Adopters Non New Drug Adopters Characteristic No. (%) No. (%) P Total number 63 (5.48) 1086 (94.52) Sex Male 21 (33.33) 545 (50.18).0093 Female 42 (66.67) 541 (49.82) Age, y (60.32) 698 (64.27) (15.87) 215 (19.80) >64 15 (23.81) 158 (14.55) Race White 49 (77.78) 853 (78.55).47 Black 12 (19.05) 165 (15.19) Other 2 (3.17) 68 (6.26) Race/ethnicity Hispanic 12 (19.05) 206 (18.97).65 Black/non-Hispanic 12 (19.05) 162 (14.92) Other 39 (61.90) 718 (66.11) Income, $ <20, (36.51) 383 (35.27).98 20,000-49, (25.40) 257 (23.66) 50, ,000 5 (7.94) 78 (7.18) >100,000 1 (1.59) 18 (1.66) Missing 18 (28.57) 350 (32.23) Insurance status Privately insured 40 (63.49) 768 (70.72).12 Publicly insured 10 (15.87) 188 (17.31) Uninsured 13 (20.63) 130 (11.97) Patients with public insurance spent 4.81 times (P.001) and 4.44 times (P.001) more, whereas those with private insurance spent 2.10 times (P =.002) and 1.94 times (P =.027) more than those patients without any healthcare insurance in terms of total and nondrug costs. DISCUSSION In this study, the association between adopting a new drug and increased healthcare expenditure was found to be significant. Results showed that patients taking new antihypertensive drugs had higher annual total healthcare costs and nondrug costs, and more ED visits than patients taking old antihypertensive drugs; however, only the total cost and nondrug cost were statistically significant. So this study refutes the VOL. 1, NO. 3 The American Journal of Pharmacy Benefits 141
5 n Ganguli Hong Table 3. Factors Affecting Differences in Use of Healthcare Resources Total Healthcare Expenditure a Nondrug Expenditure a Total Emergency Department Visits b Variable Estimate P Estimate P Estimate P Intercept 6.71 < < New drug adopters c Comorbidity index d Sex Female Reference Reference Reference Male Age, y 44 Reference Reference Reference < > < < Income, $ <20,000 Reference Reference Reference 20,000-49, , , >100, Race White Reference Reference Reference Black Other Race/ethnicity Hispanic Reference Reference Reference Black/non-Hispanic Other Insurance status Uninsured Reference Reference Reference Any private Public only 1.57 < < a Regression was done using log-transformed values. b Regression was done using ordinary least squares regression with actual values. c Reference group is the non new drug adopters. d The number of unique prescriptions was used to indicate the comorbidity index. argument that new medications reduce nondrug costs in the short run, as well as contradicting the argument that in real-world settings new antihypertensive drugs reduce ED visits compared with old medications, as concluded in some studies. 2,9 Because new drugs definitely cost more than the older medications, an increase in the total cost is understandable. However, the increase in the nondrug cost among the new drug adopters counters the argument that new drugs always are cost-effective. The increase in the nondrug cost could be explained by the increase in healthcare utilization. The results show new drug adopters have more ED visits, which though statistically insignificant could have contributed to the higher nondrug cost. Similarly, new drug adopters also may have utilized more healthcare services. In this study all drugs newly approved by the FDA in were defined as new drugs, including all new drug molecules, new product extensions, and new drug combinations still in their patent period. It is possible that these new drugs still had a high price because of ongoing or extended patent protection, but clinically they may have limited 142 The American Journal of Pharmacy Benefits Fall
6 Impact of New Antihypertensives or marginal benefits compared with the older, off-patent drugs. Of the 14 new drugs considered in this study, 7 were product extensions or new combinations rather than new chemical entities, which could have influenced the study findings. We know that product extensions and new combinations are some of the successful strategies used by companies to counter generic entry in the postpatent period. 15 Of the 1035 new drugs approved by the FDA between 1989 and 2000, 674 (65%) were modified versions of the existing drugs, according to the National Institute for Health Care Management. 16 The strategy of introducing product line extensions and new combinations has been quite successfully used to shift consumers from expired/soonto-expire original formulations. 17 We acknowledge that new breakthrough molecules are cost-effective, but that may not be true for drugs that are mere structural modifications of existing molecules. Nonadherence and compromised behavior are a few of the factors that deter drug treatment in real-world scenarios. 18 It is possible that the new drug adopters in this study had suboptimal drug adherence rates. The other factor that might explain these study findings is the lifestyle behavior of patients adopting new antihypertensive medications. Patients on new medications may have or been given an impression that the new drug will take care of their high blood pressure, and this perception enticed them to compromise the behavior modifications required as an adjunct to their drug treatment to achieve the desired outcomes. This study was adjusted for health condition (comorbidity); hence, the notion that new drug adopters had worse health was not supported. But the possibility that the new drug adopters had more severe hypertension than the non new drug adopters cannot be denied. Study patients with government-sponsored health insurance spent more than the patients with private insurance, possibly signifying overutilization of healthcare services. This difference also may be attributable to different reimbursement rates for similar services and/or Table 4. Significant Factors Affecting Differences in Use of Healthcare Resources a Variable Ratio b Total Healthcare Expenditure 1.63 (1.08, 2.47) Nondrug Expenditure 1.79 (1.12, 2.80) Unit Change in Emergency Department Visits 0.12 (0.09, 0.15) New drug adopters (95% confidence interval) Age, y 44 Reference Reference Reference > Income, $ <20,000 Reference Reference Reference 20,000-49,999 50, , >100, Race White Reference Reference Reference Black Other Insurance status Uninsured Reference Reference Reference Any private Public only a Results were significant at P.05. b Values are the natural exponential [exp(β 1 )] of the regression coefficient. products, or utilization of more costly services. Also, publicly insured hypertensive patients had more ED visits than privately insured and uninsured populations. People with higher incomes (>$50,000 per year) had the lowest total healthcare and nondrug expenditures and even fewer ED visits. Perhaps because they were affluent, they had access to and the ability to avail themselves of healthcare services and hence enjoyed better health than low-income patients. The study also found that patients older than age 64 years had higher healthcare costs, a finding supported by previous studies. 19 This study had certain limitations that may have influenced the results. MEPS data lacked information on the severity of disease. Although the results were adjusted for the comorbidity index, availability of clinical measures such as the blood pressure of the patient would have been helpful. MEPS data provide cross-sectional information; hence, the analysis was done with the assumption that all study participants had similar healthcare utilization prior to the study period. Also, new drugs were defined as those drugs approved by the FDA during the years 1996, 1997, VOL. 1, NO. 3 The American Journal of Pharmacy Benefits 143
7 n Ganguli Hong and 1998, and the study used the 1999 MEPS data. So the new drugs approved in 1996 had 3 years of effective time in the market, whereas those approved in 1997 and 1998 had 2 years and 1 year, respectively, as the effective time in the market to analyze visible impact. This difference in the effective market presence may limit the exactness of study findings. CONCLUSION Overall, adopting new antihypertensive drugs was associated with higher healthcare cost and healthcare utilization among hypertensive patients. New drugs are cost-effective when they prevent the use of more expensive healthcare resources. Certainly they are costeffective when they come as breakthroughs. However, the cost-effectiveness of new drugs has been challenged when new drugs are line extensions of existing drugs that had been successful in the market. In fact, this study sample mostly consisted of extensions rather than new breakthroughs. Further research is required to understand the exact relationship between the adoption of new antihypertensive medications and healthcare cost. The results of this study essentially suggest that prescribers of new drugs should exhibit caution before acceptance. The results also signify the need to scrutinize the pharmacoeconomic evaluation of each new drug before acceptance by formulary decision makers, payers, physicians, and pharmacy managers. Acknowledgment We thank La Marcus Wingate, PharmD, from the Department of Pharmaceutical Sciences at the University of Tennessee for his valuable assistance during the editing of this manuscript. Author Affiliations: From the Department of Pharmaceutical Sciences (AG, SHH), University of Tennessee, Memphis, TN. Dr Ganguli is now with Abbott Laboratories, Abbott Park, IL. Funding Source: None reported. Author Disclosures: The authors (AG, SHH) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article. Authorship Information: Concept and design (AG); acquisition of data (AG); analysis and interpretation of data (AG, SHH); drafting of the manuscript (AG); critical revision of the manuscript for important intellectual content (AG, SHH); statistical analysis (AG); provision of study materials or patients (AG); administrative, technical, or logistic support (AG); and supervision (SHH). Address correspondence to: Song Hee Hong, PhD, Department of Pharmaceutical Sciences, University of Tennessee, 847 Monroe Ave, Rm 205D, Memphis, TN shong6@utmem.edu. REFERENCES 1. Lichtenberg FR. The economic and human impact of new drugs. J Clin Psychiatry. 2003;64(suppl 17): Zhang Y, Soumerai SB. Do newer prescription drugs pay for themselves? A reassessment of the evidence. Health Aff (Millwood). 2007;26(3): ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178 and JAMA. 2004;291(18):2196]. JAMA. 2002;288(23): Davis BR, Piller LB, Cutler JA, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006;113(18): Heidenreich PA, Davis BR, Cutler JA, et al. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Gen Intern Med. 2008;23(5): Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA. 2003;290(2):197]. JAMA. 2003;289(19): Ganguli A, Hong SH. Profiles of initial drug therapies among newly diagnosed hypertensive patients with no compelling indications. Poster (PCV53) presented at: International Society for Pharmacoeconomics and Outcomes Research 12th Annual International Meeting; May 2007; Arlington, VA. 8. After the diagnosis: adherence and persistence with hypertension therapy. Am J Manag Care. 2005;11(13 suppl):s395-s Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff (Millwood). 2001;20(5): Miller GE, Moeller JF, Stafford RS. New cardiovascular drugs: patterns of use and association with non-drug health expenditures. Inquiry. 2005;42(4): Lichtenberg FR. Benefit and Costs of Newer Drugs: An Update. June National Bureau of Economic Research Working Paper No Accessed May 5, Center for Financing, Access and Cost Trends, Agency for Healthcare Research and Quality. MEPS HC-038: 1999 Consolidated Data File. October stats/download_data/pufs/h38/h38doc.pdf. Accessed May 5, Galson S. CDER data briefing accessible version. whatwedo/ucm pdf. Accessed May 5, CenterWatch. Approved drugs for cardiology/vascular diseases. Accessed November 13, Hong SH, Shepherd MD, Scoones D, Wan TT. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration. J Manag Care Pharm. 2005;11(9): The National Institute for Health Care Management Research and Educational Foundation. Changing Patterns of Pharmaceutical Innovation. Washington, DC: National Institute for Health Care Management; May 28, innovations.pdf. Accessed May 5, Grabowski HG, Vernon JM. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ. 1992;35(2): Lagi A, Rossi A, Passaleva MT, Cartei A, Cencetti S. Compliance with therapy in hypertensive patients. Intern Emerg Med. 2006;1(3): Hartman M, Catlin A, Lassman D, Cylus J, Heffler S. U.S. health spending by age, selected years through Health Aff (Millwood). 2008;27(1):w1-w The American Journal of Pharmacy Benefits Fall
Payers continue to search for effective ways to control
At a Glance Practical Implications p 218 Author Information p 221 Full text and PDF www.ajpblive.com Value-Based Benefit Design and Healthcare Utilization in Asthma, Hypertension, and Diabetes Benefit
More informationmedicaid and the The Role of Medicaid for People with Diabetes
on medicaid and the uninsured The Role of for People with Diabetes November 2012 Introduction Diabetes is one of the most prevalent chronic conditions and a leading cause of death in the United States.
More informationSPECIAL ISSUE. Medicaid Prescription Drug Access Restrictions: Exploring the Effect on Patient Persistence With Hypertension Medications
Medicaid Prescription Drug Access Restrictions: Exploring the Effect on Patient Persistence With Hypertension Medications Jerome Wilson, PhD; Kirsten Axelsen, MS; and Simon Tang, MPH Objective: To compare
More informationA COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH:
A COMPREHENSIVE REPORT ISSUED BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS IN PARTNERSHIP WITH: Amputee Coalition of America Mended Hearts National Federation of the Blind National Kidney Foundation
More informationALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment
1 sur 5 21/11/2009 07:26 www.medscape.com Medscape Medical News from the: American Heart Association (AHA) 2009 Scientific Sessions This coverage is not sanctioned by, nor a part of, the American Heart
More information2015 Survey on Prescription Drugs
2015 Survey on Prescription Drugs AARP Research January 26, 2016 (For media inquiries, contact Gregory Phillips at 202-434-2544 or gphillips@aarp.org) https://doi.org/10.26419/res.00122.001 Objectives
More information61 Recommendations for better use of medications
Chapter 61 Recommendations for better use of medications As stated elsewhere in this book, we are fortunate to have a number of effective medications for treatment of many medical conditions. The drug
More informationHypertension is among the most prevalent chronic
Switching Between Different ARBs in Patients With Controlled BP At a Glance Practical Implications e82 Author Information e86 Web Exclusive Original Research Khalid M. Kamal, PhD; Christopher Zacker, RPh,
More informationRole of Pharmacoepidemiology in Drug Evaluation
Role of Pharmacoepidemiology in Drug Evaluation Martin Wong MD, MPH School of Public Health and Primary Care Faculty of Medicine Chinese University of Hog Kong Outline of Content Introduction: what is
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationVirtual Mentor Ethics Journal of the American Medical Association January 2006, Volume 8, Number 1:
Virtual Mentor Ethics Journal of the American Medical Association January 2006, Volume 8, Number 1: 42-47. Policy Forum What Good Is Hypertension Screening If You Don t Do Anything about It? by Christian
More informationHave you been paying for your prescription drugs? Stop!
Dear Valued Medtipster Member: Have you been paying for your prescription drugs? Stop! Free prescription drugs are NOW just a Medtipster ID card away. Follow the steps below to obtain thousands of generic
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain
More informationDirect costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey
Direct costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey Background: Previous estimates of the cost of allergic rhinitis predate the substantial
More informationSponsored by the National Heart, Lung, and Blood Institute (NHLBI)
1 U.S. Department of Health and Human Services The Hypertension, Detection, and Follow-up Program (HDFP) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) National
More informationPre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.
Pre- Drug Use % of Treated Patients on Medication 60 50 40 30 20 10 0 1978 Diuretics ß-Blockers ACE Inhibitors Year CCBs CCBs Beta Blockers Diuretics ACE Inhibitors 1980 1982 1984 1986 1988 1990 1992 IMS
More informationTrends in Pneumonia and Influenza Morbidity and Mortality
Trends in Pneumonia and Influenza Morbidity and Mortality American Lung Association Epidemiology and Statistics Unit Research and Health Education Division November 2015 Page intentionally left blank Introduction
More informationESSAYS ON PHARMACEUTICALS AND HEALTH CARE EXPENDITURES. A Dissertation ZEYNAL KARACA
ESSAYS ON PHARMACEUTICALS AND HEALTH CARE EXPENDITURES A Dissertation by ZEYNAL KARACA Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for
More informationThe Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey
The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey by Frank R. Lichtenberg frank.lichtenberg@columbia.edu Columbia University and National Bureau of Economic
More informationMedicaid Cost Containment and Potential Effects on Diabetic Beneficiaries
Medicaid Cost Containment and Potential Effects on Diabetic Beneficiaries White Paper October 2003 2003 The Health Strategies Consultancy LLC and Duke University, The Fuqua School of Business For more
More informationHealth Care Expenditures for Adults With Multiple Treated Chronic Conditions: Estimates From the Medical Expenditure Panel Survey, 2009
Page 1 of 8 SPECIAL TOPIC Volume 10 April 25, 2013 Health Care Expenditures for Adults With Multiple Treated Chronic Conditions: Estimates From the Medical Expenditure Panel Survey, 2009 Steven R. Machlin,
More informationIn 2001, the National Cholesterol Education Program
At a Glance Practical Implications p 330 Author Information p 333 Full text and PDF www.ajpblive.com Lipid Management When Converting Fluvastatin to Pravastatin: Medication Use Evaluation Original Research
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationPer Capita Health Care Spending on Diabetes:
Issue Brief #10 May 2015 Per Capita Health Care Spending on Diabetes: 2009-2013 Diabetes is a costly chronic condition in the United States, medical costs and productivity loss attributable to diabetes
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationRe: Docket No. FDA-2009-N-0294 Regulation of Tobacco Products; Request for Comments
VIA Electronic Submission to http://www.regulations.gov September 29, 2009 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 Re: Docket
More informationSURVEY ABOUT YOUR PRESCRIPTION CHOICES
Editor s Note: This online data supplement contains supplemental material that was not included with the published article by William Shrank and colleagues, Patients' Perceptions of Generic Medications,
More informationType of intervention Secondary prevention and treatment; Other (medication coverage policy design).
Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes Rosen A B, Hamel M B, Weinstein M C, Cutler D M, Fendrick A, Vijan S Record Status
More informationUse of Antihypertensive Medications in Patients with type -2 Diabetes in Ajman, UAE
Use of Antihypertensive Medications in Patients with type -2 Diabetes in Ajman, UAE ORIGINAL ARTICLE Mohammed Arifulla 1, Lisha Jenny John 1, Jayadevan Sreedharan 2, Jayakumary Muttappallymyalil 3, Jenny
More informationMETHODS RESULTS. Supported by funding from Ortho-McNeil Janssen Scientific Affairs, LLC
PREDICTORS OF MEDICATION ADHERENCE AMONG PATIENTS WITH SCHIZOPHRENIC DISORDERS TREATED WITH TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM S.P. Lee 1 ; K. Lang 2 ; J. Jackel 2 ;
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Committee on Finance Hearing on: 10:00 a.m. National Association of Chain Drug Stores (NACDS) 1776 Wilson Blvd., Suite 200 Arlington,
More informationA Model for Comparing Unnecessary Costs Associated with Various Prescription Fill-Quantity Policies: Illustration Using VA Data
RESEARCH A Model for Comparing Unnecessary Costs Associated with Various Prescription Fill-Quantity Policies: Illustration Using VA Data OBJECTIVE: To describe a model for analyzing the unnecessary costs
More informationLike others here today, we are very conflicted on the FDA s proposal on behind-thecounter medications, but thank you for raising the issue.
Statement of Consumers Union William Vaughan, Senior Policy Analyst before the US Food and Drug Administration Public Meeting on Behind the Counter Availability of Drugs November 14, 2007 Consumers Union
More informationMedicare Severity-adjusted Diagnosis Related Groups (MS-DRGs) Coding Adjustment
American Hospital association December 2012 TrendWatch Are Medicare Patients Getting Sicker? Today, Medicare covers more than 48 million people, and that number is growing rapidly baby boomers are reaching
More informationMedication Therapy Management: Improving Health and Saving Money
Medication Therapy Management: Improving Health and Saving Money Ed Staffa, RPh Vice President, Pharmacy Mirixa Corporation estaffa@mirixa.com July 23, 2008 MTM At A Glance The U.S. health care system
More informationModernized Reference Drug Program
Modernized Reference Drug Program Monitoring Report For the period ending May 31, 2017 Issued: November 2017 Published by: Pharmaceutical Services Division and Health Sector Information, Analysis and Reporting
More informationGetting Hypertension Under Control
Getting Hypertension Under Control Learning Objectives EXPLAIN the factors involved in patient medication non-adherence. OUTLINE the results of studies focusing on medication adherence issues in patients
More informationExpenditure Share United States, 2003
Expenditure Share United States, 2003 Source: MEPS Chronic Disease Share of MEPS Expenditure ( Percent ) Share of Health Care Expenditure Breast Cancer 0.5 0.3 Colon Cancer 0.8 0.5 Lung Cancer 0.6 0.3
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationThe chronic nature of schizophrenia is a major contributor
At a Glance Practical Implications p108 Author Information p 115 Full text and PDF www.ajpblive.com Schizophrenia Costs for Newly Diagnosed Versus Previously Diagnosed Patients Treatment Costs Leslie S.
More informationPrescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines
American Journal of Pharmacology and Toxicology Original Research Paper Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines 1 Krishna Murti, 1 M. Arif Khan, 1 Akalanka Dey,
More informationSpring Understanding the potential of generic substitution
Spring 2014 Understanding the potential of generic substitution Understanding the potential of generic substitution Generic pricing reforms and the availability of generics for blockbuster drugs coming
More informationExploring the Relationship Between Substance Abuse and Dependence Disorders and Discharge Status: Results and Implications
MWSUG 2017 - Paper DG02 Exploring the Relationship Between Substance Abuse and Dependence Disorders and Discharge Status: Results and Implications ABSTRACT Deanna Naomi Schreiber-Gregory, Henry M Jackson
More informationChanges to the Eighth Edition
Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationVARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION
VARIATIONS IN PRICES AND REIMBURSEMENT OF MEDICINES IN THE EUROPEAN UNION A snapshot of data on amoxicillin, budesonide, losartan and salbutamol in eight European Union Member States Report INTRODUCTION
More informationThe standard Medicare Part D drug coverage is divided into 3
Assessment of Drug Consumption Patterns for Medicare Part D Patients Alex Pedan, PhD; Jingsong Lu, MS; and Laleh T. Varasteh, RPh, MSF The standard Medicare Part D drug coverage is divided into 3 consecutive
More informationHealthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective
More informationEffects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute Care
Effects of Antiepileptic Drug Substitutions on Epileptic Events Requiring Acute Care Karen L. Rascati, Ph.D., Kristin M. Richards, Ph.D., Michael T. Johnsrud, Ph.D., and Teresa A. Mann, Pharm.D. Study
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More informationPatient adherence to chronic disease medications in a medication therapy management program in Lucas County, Ohio
The University of Toledo The University of Toledo Digital Repository Theses and Dissertations 2009 Patient adherence to chronic disease medications in a medication therapy management program in Lucas County,
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationNational Dental Expenditure Flat Since 2008, Began to Slow in 2002
National Dental Expenditure Flat Since 2008, Began to Slow in 2002 Author: Marko Vujicic, Ph.D. The Health Policy Institute (HPI) is a thought leader and trusted source for policy knowledge on critical
More informationPharmacy Student Self-Perception of Weight and Relationship to Counseling Patients on Lifestyle Modification
RESEARCH American Journal of Pharmaceutical Education 2014; 78 (2) Article 35. Pharmacy Student Self-Perception of Weight and Relationship to Counseling Patients on Lifestyle Modification Allen Antworth,
More informationApproximately 73.6 million adults in the United States have
n clinical n Hypertension Treatment and Control Within an Independent Nurse Practitioner Setting Wendy L. Wright, MS; Joan E. Romboli, MSN; Margaret A. DiTulio, MS, MBA; Jenifer Wogen, MS; and Daniel A.
More informationThe 465 medicines in development include: 142 for diabetes, which affects 10.9 million Americans age 65 and older;
Medicines in Development Older Americans The Medicare Population and Leading Chronic Diseases presented by america s biopharmaceutical research companies Overview 2013 REPORT Biopharmaceutical Research
More informationAn estimated 20.8 million Americans 7% of the population
Provider Organization Performance Assessment Utilizing Diabetes Physician Recognition Program Bruce Wall, MD, MMM; Evelyn Chiao, PharmD; Craig A. Plauschinat, PharmD, MPH; Paul A. Miner, PharmD; James
More informationThe High Cost-related Medication Non-adherence Rate among Medicare- Medicaid Dual-eligible Diabetes Patients
Research Article imedpub Journals http://www.imedpub.com Journal of Health & Medical Economics ISSN 2471-9927 DOI: 10.21767/2471-9927.100019 The High Cost-related Medication Non-adherence Rate among Medicare-
More informationAre hypertensive elderly patients treated differently?
ORIGINAL RESEARCH Are hypertensive elderly patients treated differently? Amy DG Huebschmann 1 Caroline Bublitz 2 Robert J Anderson 1 1 University of Colorado-Denver Health Sciences Center (UCDHSC), Department
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More informationPresident Clinton's proposal for health reform contains a plan for
DataWatch Paying For Mental Health And Substance Abuse Care by Richard G. Frank, Thomas G. McGuire, Darrel A, Regier, Ronald Manderscheid, and Albert Woodward Abstract: Fifty-four billion dollars was spent
More informationChapter 10: Dialysis Providers
Chapter 10: Dialysis Providers In 2014 the two largest dialysis organizations, Fresenius and DaVita, collectively treated 69% of patients in 65% of all dialysis units (Figure 10.2). Nearly 90% of all dialysis
More informationIssue Brief. Coverage Matters: The Role of Insurance in Access to Dental Care in California. Introduction
Coverage Matters: The Role of Insurance in Access to Dental Care in California C ALIFORNIA HEALTHCARE FOUNDATION Introduction Dental insurance is the key to good oral health. People without dental insurance
More informationRESEARCH. What this study adds
RESEARCH to Type 2 Diabetes and Its Effect on Health Care Costs in Low-Income and Insured Patients with Prediabetes: A Retrospective Study Using Medicaid Claims Data Jun Wu, PhD; Eileen Ward, PharmD, BCACP;
More informationCLINICAL ARTICLE J Neurosurg Spine 27:694 699, 2017 The impact of the 2006 Massachusetts health care reform law on spine surgery patient payer-mix status and age Nicolas W. Villelli, MD, 1 Hong Yan, BS,
More informationRational Prescribing in Primary Care (RaPP): Economic Evaluation of an Intervention to Improve Professional Practice
Rational Prescribing in Primary Care (RaPP): Economic Evaluation of an Intervention to Improve Professional Practice Atle Fretheim *, Morten Aaserud, Andrew D. Oxman Norwegian Knowledge Centre for Health
More informationDoes Variation in the Physical Characteristics of Generic Drugs Affect Patients Experiences?
Does Variation in the Physical Characteristics of Generic Drugs Affect Patients Experiences? Results from a National Survey of Pharmacists and Patients Ameet Sarpatwari, J.D., Ph.D. Instructor in Medicine,
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationEliminating Barriers: Health Disparities and Solutions for African Americans
Eliminating Barriers: Health Disparities and Solutions for African Americans Gregory L. Hall, MD Chairman, Ohio Commission on Minority Health Member, Cuyahoga County Board of Health Ass t Clinical Professor,
More informationReport. Uganda Pharmaceutical Sector Scan JUNE 2010
Report On the Uganda Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments JUNE 2010 Drafted by consultants: 1. Samuel Balyejjusa, B.Pharm., MPH 2. Paschal Mujasi, B.Pharm., MBA 3.
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationMarket Distortions from the 340B Drug Pricing Program
Market Distortions from the 340B Drug Pricing Program Adam J. Fein, Ph.D. www.drugchannels.net @DrugChannels The opinions and views expressed in this presentation are those of the author and may not reflect
More informationREDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT
REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT Vida Stankus 1, Brenda Hemmelgarn 2, Norm RC Campbell 2, Guanmin Chen 2, Finlay A McAlister 1, Ross T Tsuyuki 1 1 EPICORE Centre, Department of Medicine,
More informationActual use of medications is important for payers
ORIGINAL RESEARCH and Dosing for Plaque Psoriasis and Psoriatic Arthritis Machaon Bonafede, PhD, MPH; Derek H. Tang, PhD, BSPharm; Kathleen Wilson, MPH; Alice Huang, MS; David J. Harrison, PhD; and Bradley
More informationSupport for Acetaminophen 1000 mg Over-the-Counter Dose:
Support for Acetaminophen 1000 mg Over-the-Counter Dose: The Dental Impaction Pain Model and Efficacy and Safety Results from McNeil Randomized, Double-Blind, Single-Dose Study of Acetaminophen 1000 mg,
More informationJukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at:
Hospital to Retail Spillover Analysis and Its Impact on Commercial Decision Making Jukti Kumar Kalita, PhD Business Analytics and Insights Pfizer Presented at: 1 Disclaimer The information provided and
More informationFinancial Hardship in Cancer Survivors
Financial Hardship in Cancer Survivors Robin Yabroff Robin.yabroff@hhs.gov The views expressed are those of the speaker and do not necessarily represent the official position of Department of Health and
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationRole of Insurance Coverage on Diabetes Preventive Care
European Journal of Environment and Public Health, 2017, 1(1), 02 ISSN: 2468-1997 Role of Insurance Coverage on Diabetes Preventive Care Alicestine Ashford 1, Ji Lynda Walls 1, C. Perry Brown 1, Rima Tawk
More informationTarget Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD
Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD
More informationMArch The 2014 Drug Trend Report Highlights
MArch 2015 The 2014 Drug Report Highlights Highest Increase in U.S. Drug Spend Over Past Decade In 2014, the pharmacy landscape underwent a seismic change, and the budgetary impact to healthcare payers
More informationEXECUTIVE SUMMARY ENSURING PATIENT ACCESS TO SAFE, EFFECTIVE AND AFFORDABLE PRESCRIPTION MEDICINES // 2
EXECUTIVE SUMMARY Prescription drugs play a critical role in helping to prevent, manage and cure various conditions and diseases. Today, ground-breaking medicines are profoundly improving the conditions
More informationCost of Mental Health Care
Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.
More informationHow Cost-Effective Are New Cancer Drugs in the U.S.?
How Cost-Effective Are New Cancer Drugs in the U.S.? Frank R. Lichtenberg How cost-effective are new cancer drugs in the U.S.? Frank R. Lichtenberg frl1@columbia.edu Columbia University, National Bureau
More informationUnderstanding the Value of Generic Drugs
Understanding the Value of Generic Drugs Generic drugs can help you get the most out of your health care budget. 05.02.306.1 (8/05) Many people believe that when something costs more, it must be of higher
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationNo Association between Calcium Channel Blocker Use and Confirmed Bleeding Peptic Ulcer Disease
American Journal of Epidemiology Copyright 1998 by The Johns Hopkins University School of Hygiene and Public Health All rights reserved Vol. 148, No. 4 Printed in U.S.A. A BRIEF ORIGINAL CONTRIBUTION No
More informationThe Impact of Tiered Co-Pays A Survey of Patients and Pharmacists
The Impact of Tiered Co-Pays A Survey of Patients and Pharmacists Research Report Conducted by Harris Interactive September, 2003 This study was completed on behalf of and with support from the National
More informationPharmaceutical System in the UK
Pharmaceutical System in the UK David Kullman Medicines, i Pharmacy and Industry Group Department of Health PPRI Conference, Vienna 30 September 2011 Disclaimer Conflict of interest: Nothing to disclose
More informationTask Force Finding and Rationale Statement
Cardiovascular Disease Prevention and Control: Reducing Out-of- Pocket Costs for Cardiovascular Disease Preventive Services for Patients with High Blood Pressure and High Cholesterol Task Force Finding
More informationTobacco & Poverty. Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That. Introduction. Impacts of Tobacco Use on the Poor
Policy Brief February 2018 Tobacco & Poverty Tobacco Use Makes the Poor Poorer; Tobacco Tax Increases Can Change That Introduction Tobacco use is the world s leading cause of preventable diseases and premature
More informationPrescription drug expenditures are the most rapidly growing component
Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid Kenneth S. Fink, MD, MGA, MPH 1 Patricia J. Byrns, MD 2 1 Department of Family Medicine, University of North Carolina
More informationMedicaid provides prescription drugs for certain
At a Glance Impact of Medicaid Preferred Drug List on Long-Acting Opioid Users Practical Implications p 210 Author Information p 215 Full text and PDF www.ajpblive.com Natalie R. Jacuzzi, MPH; K. John
More informationDefinition. Synonyms 9/23/2010. Trials for which the hypothesis and study design are formulated based on information needed to make a decision
Scott Ramsey, MD, PhD Definition Trials for which the hypothesis and study design are formulated based on information needed to make a decision Synonyms Pragmatic clinical trials Practical clinical trials
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationIMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE Indiana Health and Wellness Summit
IMPACT OF DRUG REBATES ON YOUR PARTICIPANTS AND YOUR PLAN RISK PROFILE 2018 Indiana Health and Wellness Summit National Diabetes Volunteer Leadership Council Who We Are Patient advocacy organization committed
More information